| Literature DB >> 17295567 |
Bonnie Spring1, Neal Doran, Sherry Pagoto, Dennis McChargue, Jessica Werth Cook, Katherine Bailey, John Crayton, Donald Hedeker.
Abstract
The study was a randomized placebo-controlled trial testing whether fluoxetine selectively enhances cessation for smokers with a history of depression. Euthymic smokers with (H+, n = 109) or without (H-, n = 138) a history of major depression received 60 mg fluoxetine or placebo plus group behavioral quit-smoking treatment for 12 weeks. Fluoxetine initially enhanced cessation for H+ smokers (p = .02) but subsequently impaired cessation regardless of depressive history. Six months after quit date, fluoxetine-treated participants were 3.3 times more likely to be smoking (p = .02). Further research is warranted to determine why high-dose fluoxetine produces continuing effects that oppose tobacco abstinence. Copyright 2007 APA, all rights reserved.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17295567 DOI: 10.1037/0022-006X.75.1.85
Source DB: PubMed Journal: J Consult Clin Psychol ISSN: 0022-006X